Experience the first and only substrate-free bioluminescent human cell lines capable of continuously and autonomously producing light.
The video below shows 490 BioTech’s autobioluminescent cells continuously reporting changes in metabolic activity over a 40-hour period. The easily identified autobioluminescent signal reveals when effects occur, how long they last, and if they are permanent. Non-destructive autobioluminescence allows the 5 samples in this example to replace 12,000 samples using older luciferin-requiring bioluminescent technologies.
490 BioTech develops patent protected light-emitting human cell lines genetically programmed to ‘report’ on biological events or interactions that affect their metabolic status.
The incorporation of these cell lines into cell culture and small animal preclinical efficacy/toxicity testing models is designed to accelerate the pace of new drug discovery and move drugs more rapidly and more effectively towards Phase I human testing with a reduced overall cost.
490 BioTech’s continuously bioluminescent cells are perfect for high throughput applications where the use of a luciferin-requiring cell line would be cost prohibitive or where sample destruction would prevent repetitive data acquisition.
Keep your animals and your IACUC happy by switching to continuously bioluminescent cells. The bioluminescence from 490 BioTech’s cell lines can be imaged through tissue, allowing you to perform small animal studies without the repeated needle sticks required from luciferin induced systems.
490 BioTech is proud to provide contract metabolic activity/toxicity services using our proprietary autobioluminescent technology.
Our autobioluminescent human tissue models continuously and non-invasively track metabolic dynamics over prolonged exposure periods to identify both pre- and post-metabolism compound effects. Contact us today to learn how we can put autobioluminescent monitoring to work for you.
Do you have a specialty or proprietary tissue that can benefit from autobioluminescent expression?
We can modify your existing cell lines to produce data continuously without costly and potentially influential substrate addition or sample destruction. We can quickly modify your samples to express an autobioluminescent phenotype and return them to your laboratory for in-house testing at a fraction of the cost of purchasing and maintaining an existing, substrate-requiring cell line.
Our revolutionary new approach to optical imaging provides you with increased data acquisition in both tissues and small animal models. By taking advantage of our continuously light producing human cell lines it has finally become possible to break free from the expensive and error prone introduction of substrate.
Get back to doing what you do best – getting data.
Autobioluminescence outperforms endpoint assays. NIH/NCATS validates 490 BioTech’s HEK293 cell line as a high-throughput drug discovery tool.
Making waves in Biotech. 490 BioTech has been recognized as one of the top 5 Highly Promising Companies of 2018 by the Pepperdine Graziadio school of business.
Easier for technicians and less painful for subjects. NC3Rs recognizes autobioluminescence as a preferred method for improving animal welfare by removing the need for repeated luciferin injections.
Putting innovation to work. The introduction of autobioluminescent technology to the marketplace in 2013 was recognized as one of the top 10 most innovative new products of the year.
We have an ever growing consortium of scientists and engineers using our cell lines to advance their innovative R&D objectives.